Adaptin Bio (APTN) Total Liabilities (2022 - 2026)
Adaptin Bio's (APTN) quarterly Total Liabilities came in at $2.6 million in Q2 2026, up 122.75% year-over-year from $1.2 million in Q2 2025, and up 6.65% quarter-over-quarter from $2.5 million in Q1 2026.
Analysis
Adaptin Bio (APTN) Total Liabilities (2022 - 2026) Analysis & Trends
Adaptin Bio has disclosed Total Liabilities across 5 years of filings, most recently posting $2.6 million for Q2 2026.
- In Q2 2026, Total Liabilities rose 122.75% year-over-year to $2.6 million; the TTM figure through Jun 2026 stood at $2.6 million (up 122.75% YoY), while the FY2025 annual figure was $2.1 million, down 51.41% from the prior year.
- Total Liabilities came in at $2.6 million for Q2 2026 at Adaptin Bio, up from $2.5 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $4.3 million in Q4 2024 to a low of $27804.0 in Q4 2022.
- Average Total Liabilities over 5 years is $1.3 million, with a median of $1.1 million recorded in 2025.
- Year-over-year, Total Liabilities surged 3730.9% in 2024 and slumped 51.41% in 2025.
- Over 5 years, Total Liabilities stood at $27804.0 in 2022, then jumped by 307.41% to $113277.0 in 2023, then surged by 3730.9% to $4.3 million in 2024, then tumbled by 51.41% to $2.1 million in 2025, then advanced by 25.53% to $2.6 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $2.6 million in Q2 2026, $2.5 million in Q1 2026, and $2.1 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 141.52 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 904.22 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 179.49 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 521.30 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 661.05 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 318.91 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 126.72 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 1.66 Bn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 132.83 Mn |
| 10 | Adaptin Bio | 56.76 Mn | 56.09 Mn | - | 2.65 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.65 Mn |
| Mar 31, 2026 | 2.48 Mn |
| Dec 31, 2025 | 2.11 Mn |
| Sep 30, 2025 | 1.86 Mn |
| Jun 30, 2025 | 1.19 Mn |
| Mar 31, 2025 | 1.11 Mn |
| Dec 31, 2024 | 4.34 Mn |
| Sep 30, 2024 | 235,640.00 |
| Jun 30, 2024 | 205,989.00 |
| Mar 31, 2024 | 170,451.00 |
| Dec 31, 2023 | 113,277.00 |
| Sep 30, 2023 | 79,122.00 |
| Dec 31, 2022 | 27,804.00 |